This post is sponsored by BioCrossroads.
Indiana’s life sciences industry has a $50 billion total impact on the state’s economy, according to recently updated data gathered by the Indiana Business Research Center at the Indiana University Kelley School of Business and BioCrossroads, Indiana’s initiative for investment, development and advancement of the state’s signature life sciences strengths.
Now with a workforce of 55,000 people at nearly 2,000 companies in the areas of drugs and pharmaceuticals, medical devices and equipment, agricultural chemicals and feedstock, medical, research and testing laboratories and biologistics*, Indiana is ranked as one of the top five states in the life sciences industry – based on the highest number of employees in the sector, the highest number of companies and the highest concentration of employees (BIO/Battelle State Bioscience Industry Development Report 2012).
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Indiana’s life sciences exports totaled $9.3 billion (one-third of Indiana’s total exports), ranking as the third highest in the United States, behind only California and Texas.
These companies are also continuing to discover and commercialize new products. There were 489 patent filings for life sciences-related innovations in 2011, and 173 new products approved by the U.S. Food and Drug Administration.
“These statistics just continue to get better for us, and demonstrate across the board that the life sciences are a robust industry and a valuable driver of Indiana’s economic growth. It is imperative that we continue the momentum, and BioCrossroads has several initiatives in progress to capitalize on our unique strengths,” said David L. Johnson, president and CEO of BioCrossroads. “These data elevate Indiana to the same company as America’s other world-renowned centers of healthcare innovation: Massachusetts, California, North Carolina and New Jersey.”
Other key findings:
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
- Indiana’s life sciences venture capital investments rose in 2012 to $64.7 million.
- The average annual wage for a life sciences worker is now $88,504, compared to $40,272 for the average private sector wage.
- Indiana life sciences workers earn nearly $5 billion in annual wages.
Indiana is home to the global headquarters for: Biomet, Cook Medical, DePuy Orthopaedics, Dow AgroSciences, Eli Lilly and Company, WellPoint, and Zimmer and the North American headquarters of Roche Diagnostics; Beckman Coulter, Boston Scientific, Covance, Express Scripts, Mead Johnson, and Medtronic have major operations located within the state.
BioCrossroads’ 2012 annual report which includes this information is available at www.biocrossroads.com
Unless otherwise noted, the most recent statistical data is from 2011.
Source: BioCrossroads/Indiana Business Research Center.
*Biologistics is a new sub-sector that BIO/Battelle added in their State Bioscience Industry Development Report 2012. BioCrossroads included biologistics as a new sub-sector for the 2011 data represented within this news release.
BioCrossroads is Indiana's initiative to grow, advance and invest in the life sciences, a public-private collaboration that supports the region's existing research and corporate strengths while encouraging new business development.
